Transdermal vs oral MHT: What difference does the treatment route make to CVD risk?
Authors say the administration method had varying effects on women's odds of a cardiovascular event.
Researchers have assessed the cardiovascular risks for a variety of hormone therapies for postmenopausal women, finding ‘diverse effects’ for different treatments.
For example, postmenopausal women who use oral oestrogen-progestogen therapy have an increased risk of heart disease and VTE within two years of starting treatment, the data suggest.
